JNJ-54175446

Cat. No.:	HY-117508		
CAS No.:	1627902-21-9		
Molecular Formula:	C ₁₈ H ₁₃ ClF ₄ N ₆ O		
Molecular Weight:	440.78		
Target:	P2X Receptor		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year

SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (2	DMSO : 62.5 mg/mL (141.79 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg		
		1 mM	2.2687 mL	11.3435 mL	22.6871 mL		
		5 mM	0.4537 mL	2.2687 mL	4.5374 mL		
		10 mM	0.2269 mL	1.1344 mL	2.2687 mL		
	Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.72 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.72 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.72 mM); Clear solution						

DIOLOGICALACITY				
Description	JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC ₅₀ s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.			
IC ₅₀ & Target	pIC50: 8.46 (hP2X7 receptor), 8.81 (rP2X7 receptor) ^[1]			
In Vitro	JNJ-54175446 (Compound 14) is a potent and selective brain penetrant P2X7 antagonist, with pIC ₅₀ s of 8.46 and 8.81 for hP2X7 and rP2X7, respectively. JNJ-54175446 shows less potent activity against mouse, dog and Macaque P2X7 (pIC ₅₀ , 7.8,			

Product Data Sheet

Ô

CI



	7.9 and 8.1, respectively) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	JNJ-54175446 shows dose-dependent occupancy with the ED ₅₀ of 0.46 mg/kg, corresponding to plasma EC ₅₀ of 105 ng/mL ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Letavic MA, et al. 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate. Send to

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA